Table 2

Published and attrition-adjusted estimates of the probability of complete remission* of diabetes after RYGB

Follow-up (years)N initialN (%) retainedN remissionReported,% (method)Data sourceAttrition-adjusted rate,% (95% CI)
Reporting cumulative remission
 Iacobellis (28)1245206 (84)5426 (AC)Clinic22 (16.8, 27.2)
 Yska (6)1280NR (54)70‖25 (KM)EMR25 (NR)
 Arterburn (17)14,434NR (87)1,645‖37 (KM)EMR37 (35.6, 38.7)
 Blackstone (16)14 months667505 (76)28156 (AC)Clinic42 (38.3, 45.8)
 Schauer (7)3221‖177 (80)14481 (AC)Clinic65 (58.7, 71.3)
 Arterburn (17)34,434NR (81)2,807‖63 (KM)EMR63 (61.5, 65.0)
 Arterburn (17)54,434NR (76)3,024‖68 (KM)EMR68 (66.4, 70.0)
Reporting prevalent remission
 Brethauer (14)1–2221‖162 (73)8452 (AC)Clinic38 (31.6, 44.4)
 Brethauer (14)3–5221‖162 (73)5031 (AC)Clinic23 (17.5, 28.6)
  • AC, available case; EMR, electronic medical record system; NR, not reported.

  • *Complete remission of type 2 diabetes as defined by HbA1c ≤6.0 (42 mmol/mol) and off all antidiabetic medications.

  • †Methods for analysis: AC and KM.

  • ‡Extreme-case imputation was used for AC analyses; KM analyses were not further adjusted.

  • ‖Estimated counts. See Supplementary Table 2 for details.